Expression and therapeutic targeting of BMI1 in canine gliomas.

Abstract

The BMI1 proto-oncogene, polycomb ring finger protein (BMI1) is a key component of the epigenetic polycomb repressor complex 1, and has been associated with aggressive behaviour and chemotherapeutic resistance in various malignances including human gliomas. Similar to humans, spontaneous canine gliomas carry a poor prognosis with limited therapeutic options. BMI1 expression and the effects of BMI1 inhibition have not been evaluated in canine gliomas. Here, we demonstrate that BMI1 is highly expressed in canine gliomas. Although increased BMI1 protein expression correlated with higher glioma grade in western blot assays, this correlation was not observed in a larger sample set using immunohistochemical analysis. The BMI1 inhibitor, PTC-209, suppressed BMI1 expression in established canine glioma cell lines and resulted in antiproliferative activity when used alone and in combination with chemotherapeutic agents. PTC-209 targeting of BMI1 activated the retinoblastoma (RB) pathway through downregulation of total and phosphorylated RB, independent of INK4A/ARF signalling, likely through BMI1-inhibition mediated upregulation of p21. These data support the rationale for targeting of BMI1 signalling and the use of canine glioma as a translational therapeutic model for human disease.

• Authors: Sami Al-Nadaf, Kyle S Peacott-Ricardos, Peter J Dickinson, Robert B Rebhun, Daniel York
• Journal: Veterinary and comparative oncology (Vet Comp Oncol) Vol. 20 Issue 4 Pg. 871-880 (Dec 2022) ISSN: 1476-5829 [Electronic] England
• PMID: 35833892 (Publication Type: Journal Article)
• Copyright: © 2022 John Wiley & Sons Ltd.

Chemical References

• Heterocyclic Compounds, 2-Ring
• Polycomb Repressive Complex 1
• PTC-209
• Thiazoles

Topics

• Animals
• Dogs
• Dog Diseases (drug therapy)
• Glioma (drug therapy, veterinary, metabolism)
• Heterocyclic Compounds, 2-Ring
• Polycomb Repressive Complex 1 (genetics)
• Thiazoles